Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer

Medical Oncology

Volumn 15, Issue 2, 1998, Pages 129-136

  Tennvall, Gunnel Ragnarson ^a   Fernberg, Jan Olof ^b  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Economic evaluation; Non small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; COST CONTROL; DRUG COST; FEVER; FLU LIKE SYNDROME; HEALTH CARE COST; HOSPITAL CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA; OUTPATIENT CARE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031712703     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02989592     Document Type: Article

References (37)

1. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer Principles & Practice of Oncology. 4th edn, Lippincott: Philadelphia, 1993 pp 673-723.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
3. Crino L. Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative Groups. Ann Oncol 1995; 6: Suppl. 3, 45-47.
4. Crino L et al. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1995; 6: 347-353.
5. Drings P. European experience with ifosfamide in non-small cell lung cancer. Semin Oncol 1989; 16: Suppl. 3, 22-30.
6. Anderson H et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1821-1826.
7. Ettinger DS. Ifosfamide in the treatment of non-small cell lung cancer. Semin Oncol 1989; 16: Suppl. 3, 31-38.
8. Crino L et al. A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990; 26: 52-56.
9. Leung WT et al. Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer. Oncology 1992; 49: 321-326.
10. Klastersky J et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1989; 7: 1087-1092.
11. Rosso R et al. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Cancer 1990; 66: 130-134.
12. Weick JK et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 1991; 9: 1157-1162.
13. Rapp E et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-641.
14. Shepherd FA. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Anticancer Drugs 1995; 6: Suppl. 6, 19-25.
15. Gatzemeier U et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996; 32A: 243-248.
16. The Oncological Centre in Southern Sweden. Manual for Chemotherapy Treatment 1993 (in Swedish) [Cytostatikamanual 1993]. The Oncological Centre in Southern Sweden: Lund 1993.
17. Eli Lilly. Gemcitabine Clinical Study Report, B9E-EW-E018. Eli Lilly: Windlesham, 1994.
18. Drummond ME, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications: OUP: Oxford, 1997.
19. Kobelt G. Health Economics. An Introduction to Economic Evaluation. Office of Health Economics: London, 1996.
20. Koch P et al. Improving efficiency in health care. New approaches in NSCLC. Health Policy Review Paper No. 8. St Mary's Hospital Medical School, London, 1994.
21. Koch P et al. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. Anti cancer Drugs 1995; 6: Suppl. 6, 49-54.
22. WHO. Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva, 1979.
23. Läkemedelsinformation AB. FASS 96. (Pharmaceuticals in Sweden), (in Swedish). Läkemedelsinformation AB: Stockholm. 1996.
24. Knobf MKT, Fischer DS, Welch-McCaffrey D. Cancer Chemotherapy. Treatment and Care. G K Hall Medical Publishers: Boston, 1984.
25. Schimpff SC. Overview of empiric antibiotic therapy for the febrile neutropenic patient. Rev Infect Dis 1985; 7: Suppl. 4, 734-740.
26. Rubenstein EB et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 3640-3646.
27. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995; 98: 224-231.
28. Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 1989; 63: 1271-1278.
29. Woods RL et al. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 61: 608-611.
30. Turrisi AT. Combined modality therapy for lung cancer: Principles to practise. The Oncologist 1997; 2: 192-194.
31. Cooper S, Georgiou V. The impact of cytotoxic chemotherapy - Perspectives from patients, specialists and nurses. Eur J Cancer 1992; 28A: Suppl. 1,36-38.
32. Griffin AM et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-195.
33. Kleinberg ML, Duafala ME. Economics of providing antineoplastic drugs in a manufacturer-mixed package. Am J Hosp Pharm 1988; 45: 109-115.
34. Eklund LH, Juneskans OT, Mellstedt H, Montelius C. Centraliserad cytostatikaberedning ger bättre service och lägre pris (in Swedish). Läkartidningen 1991; 88: 1108-1109.
35. Plumridge RJ, Maher M. Justification of a pharmacy intravenous admixture service in an Australian hospital. Am J Hosp Pharm 1993; 50: 463-466.
36. Manegold C et al. Single-agent gemcitabine versus citplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997; 8: 525-529.
37. Perng R-P et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997; 15: 2097-2102.